Notice of results

17^th Sep 2018

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it will release its interim results for the six months ended 30 June 2018 on Wednesday 19 September 2018.

Enquiries:

EKF Diagnostics Holdings plc Christopher Mills, Non-Executive Chairman Julian Baines, CEO Richard Evans, Finance Director and COO	www.ekfdiagnostics.com Tel: 00 44 29 2071 0570
N+1 Singer (Nomad & Broker) Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking)	Tel: 020 7496 3000
Walbrook PR Limited Paul McManus Lianne Cawthorne	Tel: 020 7933 8780 or Mob: 07980 541 893 / 07584 391 303

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF to showcase POCT connectivity solutions at MEDICA 2022

Powerful digital connectivity products and contract manufacturing capabilities in Hall 3 at Stand B69

EKF introduces hand-held hemoglobin analyzer with secure POC connectivity

DiaSpect Tm POC hemoglobin analyzer now powered by EKF Link digital connectivity solution

Medica 2022

Medica is the world’s largest medical trade fair. For more than 40 years it has been firmly established on every professional's calendar attracting over 40,000 delegates and over 5,000 exhibitors from 70 countries in 17 halls.

Join EKF Diagnostics at Point of Care: Innovations

Bristol, UK. 20th September 2022

Join EKF Diagnostics at AACC 2022

EKF Diagnostics exhibiting range of tests and analyzers on Booth #3637